Opinion

Video

Evolving Best Practices for ESR1 Testing

The breast cancer experts share their clinical experiences and strategies regarding the optimal timing for testing ESR1 mutations in patients with HR+/HER2- metastatic breast cancer, elaborating on how the specific points in the treatment journey at which they recommend testing influence their subsequent treatment decisions and overall approach to patient management.

  1. In your clinical practice, at what specific points in the treatment journey would you recommend testing for ESR1 mutations, and how does the timing of testing impact your subsequent treatment decisions and approach?
    • What are your institution’s protocols and best practices regarding the timing and frequency of ESR1 mutations testing throughout the treatment journey
      • Can you elaborate further on what an ESR1 mutation is?
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Andrew Davis, MD
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Adrienne G. Waks, MD, Dana-Farber Cancer Institute
A panel of 3 experts on CLL
A panel of 3 experts on CLL
Video 8 - 2 KOLs are featured in, "Emerging Trials in the Management of HR+/HER2- mBC"
Video 7 - 2 KOLs are featured in, "Adverse Event Data and Management for Optimal Quality of Life in HR+/HER2- mBC"